Answers are grounded in this paper and cite their sources.
Sonidegib, a hedgehog pathway inhibitor targeting the smoothened receptor, is widely used in advanced basal cell carcinoma (BCC). Creatine kinase (CK) elevation is a recognized adverse event following treatment with sonidegib, but its safety in patients with decompensated cirrhosis remains unclear. The present study reports the case of a 77‑year‑old man with chronic hepatitis B‑related decompensated cirrhosis who developed CK elevation after sonidegib therapy for locally advanced BCC. The patient had received oral sonidegib at 200 mg/day for 35 days, which was discontinued due to worsening ascites. Shortly afterward, the patient experienced esophagogastric variceal hemorrhage and was admitted to the Department of Hepatology at Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine (Shanghai China). At 4 days post‑admission (day 4) and 7 days after sonidegib discontinuation, CK was first found to be elevated to 3,291 U/l. The CK level peaked at 11,944 U/l on day 6, accompanied by elevated myoglobin, but without evidence of acute myocardial injury or renal impairment. Hypovolemia, electrolyte abnormality, critical disease‑associated myopathy, occult infection and concomitant medication were assessed as alternative or contributing explanations. A Naranjo Adverse Drug Reaction Probability Scale score of 4 indicated a possible adverse drug reaction. The patient received intravenous fluid replacement, permanent withdrawal of sonidegib and close monitoring. The CK level returned to the reference range by day 21, and the myoglobin level normalized by day 57; both remained normal during the 3 months of follow‑up. This case is notable for the delayed severe CK elevation after sonidegib discontinuation in the combined setting of decompensated cirrhosis and acute variceal bleeding, and highlights the importance and need for close and extended CK monitoring, careful assessment of hepatic function, and individualized treatment decisions in patients with cirrhosis receiving sonidegib.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: